Trillium Health Resources Pharmacy Prior Approval Request for



Juxtapid

Mem	ber Information
1.	Last Name: 2. First Name: Trillium ID #: 4. Date of Birth: 5. Gender:
3.	Trillium ID #: 5. Gender: 5. Gender:
Presc	criber Information
1.	Prescriber Name: 2. NPI #:
3.	Requestor Name (Nurse/Office Staff): City: State: Zip:
4.	Mailing Address: State: Zip:
5.	Phone #: Ext Fax #:
Drug Information	
1. D	rug Name: <u>Juxtapid</u> 2. Strength: 3. Quantity Per 30 Days:
4. Le	ength of Therapy (in Days): □ up to 30 Days □ 60 Days □ 90 Days □ 120 Days □ 180 Days □ 365 Days
Clinic	cal Information
1.	Has the recipient been diagnosed with homozygous familial hypercholesterolemia (HoFH)? \square Yes \square No
2.	Is the recipient enrolled in the Juxtapid REMS program? ☐ Yes ☐ No
3.	Is the recipient at least 18 years old or older? ☐ Yes ☐ No
4.	Is the recipient female? ☐ Yes ☐ No (if Yes, then answer 4a; if No then move to question 5)
	a. If female, has a negative pregnancy test been obtained? □ Yes □ No
5.	Has a measurement of the recipient's ALT, AST, alkaline phosphatase, and total bilirubin been obtained before
	initiating treatment? ☐ Yes ☐ No
	a. ALT level: (U/L)
	b. AST level: (U/L)
	c. Alkaline phosphatase level: (U/L)
	d. Bilirubin level: (mg/dL)
6.	For reauthorization:
	a. During the first year, has the recipient received liver-related tests (ALT and AST, at a minimum) prior to each
	increase in dose or monthly, whichever occurs first? ☐ Yes ☐ No
	b. After the first year, has the recipient received these tests at least every 3 months and before any increase in
	dose? □ Yes □ No
7.	Failed two preferred drug(s). List preferred drugs failed:and/or
	a. □ Allergic Reaction and/or
	b. Drug-to-drug interaction. Please describe reaction(s):
8.	Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:
9.	Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s).
	Please provide Clinical information:
10.	Age specific indications. Please give patient age and explain:
	Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a
	general reference:
12.	Unacceptable clinical risk associated with therapeutic change. Please explain:
Sig	nature of Prescriber: Date:
J	

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.